Management of Severe Hypertriglyceridemia

Initial Treatment and Monitoring

The American College of Cardiology recommends rechecking the fasting lipid panel in 4-8 weeks after initiating fenofibrate therapy and implementing aggressive lifestyle modifications for a triglyceride level of 700 mg/dL 1, 2, 3
For patients with severe hypertriglyceridemia (500-999 mg/dL), fenofibrate 54-160 mg daily must be initiated immediately as first-line therapy to prevent acute pancreatitis, regardless of LDL cholesterol levels or cardiovascular risk profile 1, 2, 3
The primary goal at the first recheck is to reduce triglycerides to <500 mg/dL to eliminate the immediate pancreatitis risk, with a secondary goal of achieving triglycerides <200 mg/dL to reduce long-term cardiovascular risk 1, 2, 3

The American College of Cardiology recommends restricting total dietary fat to 20-25% of total daily calories, eliminating all added sugars, and complete abstinence from alcohol for patients with severe hypertriglyceridemia 1, 2, 3
Targeting 5-10% body weight reduction can produce a 20% decrease in triglycerides and is the single most effective lifestyle intervention 1, 2, 3
Engaging in at least 150 minutes per week of moderate-intensity aerobic activity can reduce triglycerides by approximately 11% 1, 2

If triglycerides remain >200 mg/dL after 3 months of optimized therapy, adding prescription omega-3 fatty acids (icosapent ethyl 2-4g daily) as adjunctive therapy may be considered, especially for patients with established cardiovascular disease or diabetes with ≥2 additional cardiovascular risk factors 1, 2, 3
The American College of Cardiology recommends rechecking lipid panels every 6-12 months to ensure sustained control once triglycerides are stabilized <200 mg/dL 2
When combining fenofibrate with statin therapy, using lower statin doses and monitoring for muscle symptoms and CK levels is recommended to minimize myopathy risk 1, 2